Re: Efficacy of Everolimus in Advanced Renal Cell Carcinoma: A Double-Blind, Randomised, Placebo-Controlled Phase III Trial

被引：1

作者：

Pouliot, Frederic ^{[1
]}

Pantuck, Allan J. ^{[1
]}

机构：

[1] Univ Calif Los Angeles, David Geffen Sch Med, Dept Urol, Los Angeles, CA 90095 USA

来源：

EUROPEAN UROLOGY | 2009年 / 55卷 / 06期

关键词：

D O I：

10.1016/j.eururo.2009.03.034

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1482 / 1484

页数：3

共 50 条

[31] Folic acid supplementation in postmenopausal women with hot flushes: phase III randomised double-blind placebo-controlled trial
Ewies, A. A. A.
Ahmed, I
Al-Azzawi, F.
Pitkin, J.
Gupta, P.
Persic, M.
Sahu, B.
Elgobashy, A.
Barraclough, L.
Woodman, J.
Babrah, J.
Bowden, S.
Stocken, D.
Billingham, L.
Sundar, S.
Rea, D.
BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2021, 128 (12) : 2024 - 2033
[32] Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial
Blay, Jean-Yves
Serrano, Cesar
Heinrich, Michael C.
Zalcberg, John
Bauer, Sebastian
Gelderblom, Hans
Schoffski, Patrick
Jones, Robin L.
Attia, Steven
D'Amato, Gina
Chi, Ping
Reichardt, Peter
Meade, Julie
Shi, Kelvin
Ruiz-Soto, Rodrigo
George, Suzanne
von Mehren, Margaret
LANCET ONCOLOGY, 2020, 21 (07): : 923 - 934
[33] Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial
Colombo, Nicoletta
Biagioli, Elena
Harano, Kenichi
Galli, Francesca
Hudson, Emma
Antill, Yoland
Choi, Chel Hun
Rabaglio, Manuela
Marme, Frederic
Marth, Christian
Parma, Gabriella
Farinas-Madrid, Lorena
Nishio, Shin
Allan, Karen
Lee, Yeh Chen
Piovano, Elisa
Pardo, Beatriz
Nakagawa, Satoshi
Mcqueen, John
Zamagni, Claudio
Manso, Luis
Takehara, Kazuhiro
Tasca, Giulia
Ferrero, Annamaria
Tognon, Germana
Lissoni, Andrea Alberto
Petrella, Mariacristina
Laudani, Maria Elena
Rulli, Eliana
Uggeri, Sara
Ginesta, M. Pilar Barretina
LANCET ONCOLOGY, 2024, 25 (09): : 1135 - 1146
[34] Efficacy and Safety of Sovateltide in Patients with Acute Cerebral Ischaemic Stroke: A Randomised, Double-Blind, Placebo-Controlled, Multicentre, Phase III Clinical Trial
Gulati, Anil
Adwani, Sikandar Gokuldas
Vijaya, Pamidimukkala
Agrawal, Nilesh Radheshyam
Ramakrishnan, T. C. R.
Rai, Hari Prakash
Jain, Dinesh
Sundarachary, Nagarjunakonda Venkata
Pandian, Jeyaraj Durai
Sardana, Vijay
Sharma, Mridul
Sidhu, Gursaran Kaur
Anand, Sidharth Shankar
Vibha, Deepti
Aralikatte, Saroja
Khurana, Dheeraj
Joshi, Deepika
Karadan, Ummer
Siddiqui, Mohd. Shafat Imam
DRUGS, 2024, : 1637 - 1650
[35] Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial
Wallace, Daniel J.
Furie, Richard A.
Tanaka, Yoshiya
Kalunian, Kenneth C.
Mosca, Marta
Petri, Michelle A.
Doerner, Thomas
Cardiel, Mario H.
Bruce, Ian N.
Gomez, Elisa
Carmack, Tara
DeLozier, Amy M.
Janes, Jonathan M.
Linnik, Matthew D.
de Bono, Stephanie
Silk, Maria E.
Hoffman, Robert W.
LANCET, 2018, 392 (10143): : 222 - 231
[36] Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial
Kappos, Ludwig
Hartung, Hans-Peter
Freedman, Mark S.
Boyko, Alexey
Radue, Ernst Wilhelm
Mikol, Daniel D.
Lamarine, Marc
Hyvert, Yann
Freudensprung, Ulrich
Plitz, Thomas
van Beek, Johan
LANCET NEUROLOGY, 2014, 13 (04): : 353 - 363
[37] Efficacy of elafibranor in primary biliary cholangitis: results from the variable double-blind period of ELATIVE®, a randomised, placebo-controlled phase III trial
Bowlus, Christopher L.
Kowdley, Kris V.
Levy, Cynthia
Akarca, Ulus
Alvares-da-Silva, Mario
Andreone, Pietro
Arrese, Marco
Corpechot, Christophe
Francque, Sven
Heneghan, Michael
Invernizzi, Pietro
Jones, David
Kruger, Frederik
Lawitz, Eric
Mayo, Marlyn J.
Shiffman, Mitchell
Swain, Mark G.
Miguel Valera, Jose
Vargas Blasco, Victor
Vierling, John M.
Villamil, Alejandra
Dietrich, Julie
Shu, Jianfen
Antunes, Nuno
Sleiman, Marwan
Touati, Nathan
Schattenberg, Joern M.
JOURNAL OF HEPATOLOGY, 2024, 80 : S80 - S80
[38] Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial
Meininger, Vincent
Genge, Angela
van den Berg, Leonard H.
Robberecht, Wim
Ludolph, Albert
Chio, Adriano
Kim, Seung H.
Leigh, P. Nigel
Kiernan, Matthew C.
Shefner, Jeremy M.
Desnuelle, Claude
Morrison, Karen E.
Petri, Susanne
Boswell, Diane
Temple, Jane
Mohindra, Rajat
Davies, Matt
Bullman, Jonathan
Rees, Paul
Lavrov, Arseniy
LANCET NEUROLOGY, 2017, 16 (03): : 208 - 216
[39] Efficacy and safety of odevixibat in patients with Alagille syndrome (ASSERT): a phase 3, double-blind randomised, placebo-controlled trial
Ovchinsky, Nadia
Aumar, Madeleine
Baker, Alastair
Baumann, Ulrich
Butler, Philip
Cananzi, Mara
Czubkowski, Piotr
Durmaz, Oezlem
Fischer, Ryan
Indolfi, Giuseppe
Karnsakul, Wikrom W.
Lacaille, Florence
Lee, Way S.
Maggiore, Giuseppe
Rosenthal, Philip
Ruiz, Mathias
Sokal, Etienne
Sturm, Ekkehard
Woerd, Wendy van der
Verkade, Henkjan J.
Wehrman, Andrew
Clemson, Christine
Yu, Qifeng
Ni, Quanhong
Ruvido, Jessica
Manganaro, Susan
Mattsson, Jan P.
LANCET GASTROENTEROLOGY & HEPATOLOGY, 2024, 9 (07): : 632 - 645
[40] Safety and efficacy of amiselimod in relapsing multiple sclerosis (MOMENTUM): a randomised, double-blind, placebo-controlled phase 2 trial
Kappos, Ludwig
Arnold, Douglas L.
Bar-Or, Amit
Camm, John
Derfuss, Tobias
Kieseier, Bernd C.
Sprenger, Till
Greenough, Kristin
Ni, Pingping
Harada, Tomohiko
LANCET NEUROLOGY, 2016, 15 (11): : 1148 - 1159

← 1 2 3 4 5 →